SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Frances Eun-Hyung Lee, John J. Treanor, Murray and Nadel's Textbook of Respiratory Medicine, 2016,

    CrossRef

  2. 2
    R. San-Juan, D. Navarro, A. García-Reyne, M. Montejo, P. Muñoz, J. Carratala, O. Len, J. Fortun, B. Muñoz-Cobo, E. Gimenez, A. Eworo, N. Sabe, Y. Meije, P. Martín-Davila, A. Andres, J. Delgado, C. Jimenez, P. Amat, M. Fernández-Ruiz, F. López-Medrano, C. Lumbreras, J.M. Aguado, Effect of delaying prophylaxis against CMV in D+/R− solid organ transplant recipients in the development of CMV-specific cellular immunity and occurrence of late CMV disease, Journal of Infection, 2015, 71, 5, 561

    CrossRef

  3. 3
    R. San-Juan, D. Navarro, A. García-Reyne, M. Montejo, P. Muñoz, J. Carratala, O. Len, J. Fortun, B. Muñoz-Cobo, E. Gimenez, A. Eworo, N. Sabe, Y. Meije, P. Martín-Davila, A. Andres, J. Delgado, C. Jimenez, P. Amat, M. Fernández-Ruiz, F. López-Medrano, C. Lumbreras, J.M. Aguado, Effect of long-term prophylaxis in the development of cytomegalovirus-specific T-cell immunity in D+/R− solid organ transplant recipients, Transplant Infectious Disease, 2015, 17, 5
  4. 4
    Steven Gabardi, Natalya Asipenko, James Fleming, Kevin Lor, Lisa McDevitt-Potter, Anisa Mohammed, Christin Rogers, Eric M. Tichy, Renee Weng, Ruth-Ann Lee, Evaluation of Low- Versus High-dose Valganciclovir for Prevention of Cytomegalovirus Disease in High-risk Renal Transplant Recipients, Transplantation, 2015, 99, 7, 1499

    CrossRef

  5. 5
    D.R. Stevens, D. Sawinski, E. Blumberg, N. Galanakis, R.D. Bloom, J. Trofe-Clark, Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis, Transplant Infectious Disease, 2015, 17, 2
  6. 6
    Curtis D. Holt, Drew J. Winston, Transplantation of the Liver, 2015,

    CrossRef

  7. 7
    Heather E. Vezina, Richard C. Brundage, Henry H. Balfour, Population pharmacokinetics of valganciclovir prophylaxis in paediatric and adult solid organ transplant recipients, British Journal of Clinical Pharmacology, 2014, 78, 2
  8. 8
    Lluis Guirado-Perich, Constantino Fernández-Rivera, Julián Torre-Cisneros, Eliazar Sabater-Cabrera, Elena Ruiz-Beato, Cristina Varela, Análisis coste-utilidad de valganciclovir durante 200 días frente a 100 días post-trasplante como tratamiento preventivo de la enfermedad por citomegalovirus en receptores de trasplante renal de alto riesgo, PharmacoEconomics Spanish Research Articles, 2013, 10, 1, 15

    CrossRef

  9. 9
    Young Bin Joo, Hong Soon Jung, Myong Ki Baeg, Wook Hyun Lee, Hwa Jeong Lee, Chul Woo Yang, Cytomegalovirus esophagitis presents as chest pain in a renal transplant recipient, The Korean Journal of Internal Medicine, 2013, 28, 4, 497

    CrossRef

  10. 10
    Samira M. Fallatah, Max A. Marquez, Fateh Bazerbachi, Jeffrey R. Schiff, Mark S. Cattral, Ian D. McGilvray, Andrea Norgate, Markus Selzner, Coleman Rotstein, Shahid Husain, Cytomegalovirus infection post-pancreas–kidney transplantation – results of antiviral prophylaxis in high-risk patients, Clinical Transplantation, 2013, 27, 4
  11. 11
    Hargobind S. Khurana, Alison Kole, Jeremy Falk, Sara Ghandehari, Guy Soohoo, Sinan Simsir, Wen Cheng, Robert M. Kass, Jasjit Khurana, George Chaux, Low-Dose Valganciclovir for CMV Prophylaxis after Lung Transplantation, ISRN Transplantation, 2013, 2013, 1

    CrossRef

  12. 12
    F.L. Luan, Six-Month Low-Dose Valganciclovir Prophylaxis in Cytomegalovirus D+/R− Kidney Transplant Patients Receiving Thymoglobulin Induction, Transplantation Proceedings, 2013, 45, 1, 175

    CrossRef

  13. 13
    Antonio Ríos, Beatriz Febrero, Pablo Ramírez, Jose Rodriguez, Ricardo Robles, Francisco Bueno, José Medina, Antonio Capel, Pascual Parrilla, Successful embolization of a cytomegalovirus-related duodenal ulcer in a kidney-pancreas transplant recipient, Progress in Transplantation, 2013, 23, 3, 217

    CrossRef

  14. 14
    Andre C. Kalil, Cezarina Mindru, Jean F. Botha, Wendy J. Grant, David F. Mercer, Marco A. Olivera, Megan A. McCartan, Timothy M. McCashland, Alan N. Langnas, Diana F. Florescu, Risk of cytomegalovirus disease in high-risk liver transplant recipients on valganciclovir prophylaxis: A systematic review and meta-analysis, Liver Transplantation, 2012, 18, 12
  15. 15
    V. Müller, A. Perrakis, J. Meyer, T. Förtsch, K. Korn, R.S. Croner, S. Yedibela, W. Hohenberger, V.S. Schellerer, The Value of Pre-emptive Therapy for Cytomegalovirus after Liver Transplantation, Transplantation Proceedings, 2012, 44, 5, 1357

    CrossRef

  16. 16
    Chad R. Gordon, Robin K. Avery, William Abouhassan, Maria Siemionow, Cytomegalovirus and Other Infectious Issues Related to Face Transplantation: Specific Considerations, Lessons Learned, and Future Recommendations, Plastic and Reconstructive Surgery, 2011, 127, 4, 1515

    CrossRef

  17. 17
    A. C. Kalil, C. Mindru, D. F. Florescu, Effectiveness of Valganciclovir 900 mg versus 450 mg for Cytomegalovirus Prophylaxis in Transplantation: Direct and Indirect Treatment Comparison Meta-analysis, Clinical Infectious Diseases, 2011, 52, 3, 313

    CrossRef

  18. 18
    Ajay K. Parsaik, Tajinder Bhalla, Ming Dong, Nassir Rostambeigi, Ross A. Dierkhising, Patrick Dean, Roshini Abraham, Mikel Prieto, Walter K. Kremers, Raymund R. Razonable, Yogish C. Kudva, Epidemiology of Cytomegalovirus Infection After Pancreas Transplantation, Transplantation, 2011, 1

    CrossRef

  19. 19
    Pamala A. Jacobson, David Schladt, William S. Oetting, Robert Leduc, Weihau Guan, Arthur J. Matas, Vishal Lamba, Roslyn B. Mannon, Bruce A. Julian, Ajay Israni, Genetic Determinants of Mycophenolate-Related Anemia and Leukopenia After Transplantation, Transplantation, 2011, 91, 3, 309

    CrossRef

  20. You have free access to this content20
    F. L. Luan, M. Kommareddi, A. O. Ojo, Impact of Cytomegalovirus Disease in D+/R– Kidney Transplant Patients Receiving 6 Months Low-Dose Valganciclovir Prophylaxis, American Journal of Transplantation, 2011, 11, 9
  21. 21
    S. Nasiri, S.F. Ahmadi, M. Lessan-Pezeshki, S. Seyfi, S. Alatab, Lack of Cytomegalovirus and Polyomavirus Coexistence in Iranian Kidney Transplant Recipients, Transplantation Proceedings, 2011, 43, 2, 536

    CrossRef

  22. 22
    A.A. Boudreault, H. Xie, R.M. Rakita, J.D. Scott, C.L. Davis, M. Boeckh, A.P. Limaye, Risk factors for late-onset cytomegalovirus disease in donor seropositive/recipient seronegative kidney transplant recipients who receive antiviral prophylaxis, Transplant Infectious Disease, 2011, 13, 3
  23. 23
    Ilkka Helanterä, Irmeli Lautenschlager, Petri Koskinen, The risk of cytomegalovirus recurrence after kidney transplantation, Transplant International, 2011, 24, 12
  24. 24
    Omar J. BenMarzouk-Hidalgo, José M. Cisneros, Elisa Cordero, Almudena Martín-Peña, Berta Sanchez, Cecilia Martin-Gandul, Miguel A. Gentil, Miguel A. Gomez-Bravo, Ernesto Lage, Pilar Perez-Romero, Therapeutic Effect of the Acquisition of Cytomegalovirus-Specific Immune Response During Preemptive Treatment, Transplantation, 2011, 91, 8, 927

    CrossRef

  25. 25
    C.R. Gordon, W. Abouhassan, R.K. Avery, What Is The True Significance of Donor-Related Cytomegalovirus Transmission in the Setting of Facial Composite Tissue Allotransplantation?, Transplantation Proceedings, 2011, 43, 9, 3516

    CrossRef

  26. 26
    Dimitra Mitsani, M. Hong Nguyen, Eun J. Kwak, Fernanda P. Silveira, Aniket Vadnerkar, Joseph Pilewski, Maria Crespo, Yoshiya Toyoda, Christian Bermudez, Cornelius J. Clancy, Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis, The Journal of Heart and Lung Transplantation, 2010, 29, 9, 1014

    CrossRef

  27. 27
    Robert J. Stratta, Carolynn Pietrangeli, G. Mark Baillie, Defining the Risks for Cytomegalovirus Infection and Disease After Solid Organ Transplantation, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2010, 30, 2
  28. 28
    Hugo Weclawiak, Catherine Mengelle, Abdellatif Ould Mohamed, Jacques Izopet, Lionel Rostaing, Nassim Kamar, Effets du cytomégalovirus en transplantation et place de la prophylaxie antivirale, Néphrologie & Thérapeutique, 2010, 6, 6, 505

    CrossRef

  29. 29
    Atul Humar, Ajit P. Limaye, Emily A. Blumberg, Ingeborg A. Hauser, Flavio Vincenti, Alan G. Jardine, Daniel Abramowicz, Jane A. L. Ives, Mahdi Farhan, Patrick Peeters, Extended Valganciclovir Prophylaxis in D+/R− Kidney Transplant Recipients is Associated With Long-Term Reduction in Cytomegalovirus Disease: Two-Year Results of the IMPACT Study, Transplantation, 2010, 90, 12, 1427

    CrossRef

  30. 30
    Hugo Weclawiak, Nassim Kamar, Catherine Mengelle, Laure Esposito, Abdellatif Ould Mohamed, Laurence Lavayssiere, David Ribes, Olivier Cointault, Marie-Béatrice Nogier, Isabelle Cardeau-Desangles, Jacques Izopet, Lionel Rostaing, Pre-emptive intravenous ganciclovir versus valganciclovir prophylaxis for de novo cytomegalovirus-seropositive kidney-transplant recipients, Transplant International, 2010, 23, 10
  31. 31
    I. Helanterä, L. Kyllönen, I. Lautenschlager, K. Salmela, P. Koskinen, Primary CMV Infections Are Common in Kidney Transplant Recipients After 6 Months Valganciclovir Prophylaxis, American Journal of Transplantation, 2010, 10, 9
  32. 32
    E. Lapidus-Krol, R. Shapiro, J. Amir, M. Davidovits, R. Steinberg, E. Mor, Y. Avitzur, The efficacy and safety of valganciclovir vs. oral ganciclovir in the prevention of symptomatic CMV infection in children after solid organ transplantation, Pediatric Transplantation, 2010, 14, 6
  33. 33
    M. D. Pescovitz, Valganciclovir: Recent Progress, American Journal of Transplantation, 2010, 10, 6
  34. 34
    F. Eun-Hyung Lee, John Treanor, Murray and Nadel's Textbook of Respiratory Medicine, 2010,

    CrossRef

  35. 35
    R. San Juan, M. Yebra, C. Lumbreras, F. López-Medrano, M. Lizasoain, J.C. Meneu, J. Delgado, A. Andrés, J.M. Aguado, A new strategy of delayed long-term prophylaxis could prevent cytomegalovirus disease in (D+/R−) solid organ transplant recipients, Clinical Transplantation, 2009, 23, 5
  36. 36
    Shahid Husain, Carolynn E. Pietrangeli, Adriana Zeevi, Delayed onset CMV disease in solid organ transplant recipients, Transplant Immunology, 2009, 21, 1, 1

    CrossRef

  37. 37
    Raymund Rabe Razonable, Management of Cytomegalovirus Infection After Renal Transplantation, Infectious Diseases in Clinical Practice, 2009, 17, 4, 220

    CrossRef

  38. 38
    Olivier Preynat-Seauve, Pierre R. Burkhard, Jean Villard, Walter Zingg, Nathalie Ginovart, Anis Feki, Michel Dubois-Dauphin, Samia A. Hurst, Alex Mauron, Marisa Jaconi, Karl-Heinz Krause, Pluripotent stem cells as new drugs? The example of Parkinson's disease, International Journal of Pharmaceutics, 2009, 381, 2, 113

    CrossRef

  39. 39
    M.C. Ar, M. Ozbalak, N. Tuzuner, H. Bekoz, O. Ozer, K. Ugurlu, F. Tabak, B. Ferhanoglu, Severe Bone Marrow Failure Due to Valganciclovir Overdose After Renal Transplantation From Cadaveric Donors: Four Consecutive Cases, Transplantation Proceedings, 2009, 41, 5, 1648

    CrossRef

  40. 40
    S. K. Arthurs, A. J. Eid, R. A. Pedersen, W. K. Kremers, F. G. Cosio, R. Patel, R. R. Razonable, Delayed-Onset Primary Cytomegalovirus Disease and the Risk of Allograft Failure and Mortality after Kidney Transplantation, Clinical Infectious Diseases, 2008, 46, 6, 840

    CrossRef

  41. 41
    Rafael San Juan, José Maria Aguado, Carlos Lumbreras, Jesus Fortun, Patricia Muñoz, Joan Gavalda, Francisco Lopez-Medrano, Miguel Montejo, German Bou, Marino Blanes, Antonio Ramos, Asuncion Moreno, Julian Torre-Cisneros, Jorge Carratalá, Impact of Current Transplantation Management on the Development of Cytomegalovirus Disease after Renal Transplantation, Clinical Infectious Diseases, 2008, 47, 7, 875

    CrossRef

  42. 42
    C. Legendre, M. Pascual, Improving Outcomes for Solid-Organ Transplant Recipients At Risk from Cytomegalovirus Infection: Late-Onset Disease and Indirect Consequences, Clinical Infectious Diseases, 2008, 46, 5, 732

    CrossRef

  43. 43
    S. Brum, F. Nolasco, J. Sousa, A. Ferreira, M. Possante, J.R. Pinto, E. Barroso, J.R. Santos, Leukopenia in Kidney Transplant Patients With the Association of Valganciclovir and Mycophenolate Mofetil, Transplantation Proceedings, 2008, 40, 3, 752

    CrossRef

  44. 44
    C. E. Chamberlain, S. R. Penzak, R. M. Alfaro, R. Wesley, C. E. Daniels, D. Hale, A. D. Kirk, R. B. Mannon, Pharmacokinetics of Low and Maintenance Dose Valganciclovir in Kidney Transplant Recipients, American Journal of Transplantation, 2008, 8, 6
  45. 45
    H-Y. Sun, M. M. Wagener, N. Singh, Prevention of Posttransplant Cytomegalovirus Disease and Related Outcomes with Valganciclovir: A Systematic Review, American Journal of Transplantation, 2008, 8, 10
  46. 46
    I. Helantera, I. Lautenschlager, P. Koskinen, Prospective follow-up of primary CMV infections after 6 months of valganciclovir prophylaxis in renal transplant recipients, Nephrology Dialysis Transplantation, 2008, 24, 1, 316

    CrossRef

  47. 47
    Yafit Partouche Avidan, Mical Paul, Ruth Rahamimov, Jihad Bishara, Zmira Samra, Scherf Edna, Eytan Mor, Selective low-dose valganciclovir for prevention of cytomegalovirus disease following kidney transplantation, Journal of Infection, 2008, 57, 3, 236

    CrossRef

  48. 48
    R. Trappe, H. Pohl, A. Forberger, R. Schindler, P. Reinke, Acute esophageal necrosis (black esophagus) in the renal transplant recipient: manifestation of primary cytomegalovirus infection, Transplant Infectious Disease, 2007, 9, 1
  49. 49
    Francis L. Weng, Anup M. Patel, A Scott Mathis, Authors?? Reply, Transplantation, 2007, 84, 1, 126

    CrossRef

  50. 50
    C. Steininger, Clinical relevance of cytomegalovirus infection in patients with disorders of the immune system, Clinical Microbiology and Infection, 2007, 13, 10
  51. 51
    M.A. Moreno de la Higuera Díaz, N. Calvo Romero, A. Sánchez-Fructuoso, J. Conesa, M. Marques Vidas, D. Prats, A. Barrientos Guzmán, Cytomegalovirus Infection in Seronegative Patients Treated With Prophylaxis: Case-Controlled Study, Transplantation Proceedings, 2007, 39, 7, 2231

    CrossRef

  52. 52
    C. Cervera, M. Pineda, L. Linares, M.A. Marcos, C. Esteva, A. Antón, F. Cofán, M.J. Ricart, M. Navasa, F. Pérez-Villa, T. Pumarola, A. Moreno, Impact of Valganciclovir Prophylaxis on the Development of Severe Late-Cytomegalovirus Disease in High-Risk Solid Organ Transplant Recipients, Transplantation Proceedings, 2007, 39, 7, 2228

    CrossRef

  53. 53
    F. Li, K. W. Kenyon, K. A. Kirby, D. P. Fishbein, M. Boeckh, A. P. Limaye, Incidence and Clinical Features of Ganciclovir- Resistant Cytomegalovirus Disease in Heart Transplant Recipients, Clinical Infectious Diseases, 2007, 45, 4, 439

    CrossRef

  54. 54
    Mark D. Pescovitz, Is Low-Dose Valganciclovir the Same as Appropriate-Dose Valganciclovir?, Transplantation, 2007, 84, 1, 126

    CrossRef

  55. 55
    Pascal R Meylan, Oriol Manuel, Late-onset cytomegalovirus disease in patients with solid organ transplant, Current Opinion in Infectious Diseases, 2007, 20, 4, 412

    CrossRef

  56. 56
    Jennifer K. Walker, Lisa M. Scholz, Marc H. Scheetz, Lorenzo G. Gallon, Dixon B. Kaufman, Erik J. Rachwalski, Michael M. Abecassis, Joseph R. Leventhal, Leukopenia Complicates Cytomegalovirus Prevention After Renal Transplantation With Alemtuzumab Induction, Transplantation, 2007, 83, 7, 874

    CrossRef

  57. 57
    Francis L. Weng, Anup M. Patel, Rimda Wanchoo, Yasmin Brahmbhatt, Kezia Ribeiro, Marc E. Uknis, Shamkant Mulgaonkar, A Scott Mathis, Oral Ganciclovir Versus Low-Dose Valganciclovir for Prevention of Cytomegalovirus Disease in Recipients of Kidney and Pancreas Transplants, Transplantation, 2007, 83, 3, 290

    CrossRef

  58. 58
    Karin M. Fuchs, Danny Wu, Zeynep Ebcioglu, Pregnancy in Renal Transplant Recipients, Seminars in Perinatology, 2007, 31, 6, 339

    CrossRef

  59. 59
    Abdolreza Haririan, Katherina Morawski, Miguel S. West, Jose M. El-Amm, Mona D. Doshi, Elizabeth Cincotta, George J. Alangaden, Pranatharthi Chandrasekar, Scott A. Gruber, Sirolimus exposure during the early post-transplant period reduces the risk of CMV infection relative to tacrolimus in renal allograft recipients, Clinical Transplantation, 2007, 21, 4
  60. 60
    Alden M. Doyle, Karen M. Warburton, Simin Goral, Emily Blumberg, Robert A. Grossman, Roy D. Bloom, 24-Week Oral Ganciclovir Prophylaxis in Kidney Recipients Is Associated with Reduced Symptomatic Cytomegalovirus Disease Compared to a 12-Week Course, Transplantation, 2006, 81, 8, 1106

    CrossRef

  61. 61
    Rafael San Juan Garrido, Jose M. Aguado, Carmen D??az-Pedroche, Oscar Len, Miguel Montejo, Asuncion Moreno, Mercedes Gurgu??, Julian Torre-Cisneros, Felipe Pareja, Javier Segovia, Milagros Garcia, Carlos Lumbreras, A Review of Critical Periods for Opportunistic Infection in the New Transplantation Era, Transplantation, 2006, 82, 11, 1457

    CrossRef

  62. 62
    Maria Cristina Keightley, Charles Rinaldo, Arlene Bullotta, James Dauber, Kirsten St. George, Clinical utility of CMV early and late transcript detection with NASBA in bronchoalveolar lavages, Journal of Clinical Virology, 2006, 37, 4, 258

    CrossRef

  63. 63
    J. Carstens, H.K. Andersen, E. Spencer, M. Madsen, Cytomegalovirus infection in renal transplant recipients, Transplant Infectious Disease, 2006, 8, 4
  64. 64
    Pascal R.-A. Meylan, Manuel Pascual, Editorial Commentary:Preemptive versus Prophylactic Approaches in the Management of Cytomegalovirus Disease in Solid Organ Transplant Recipients: What We Know and What We Do Not Know, Clinical Infectious Diseases, 2006, 43, 7, 881

    CrossRef

  65. 65
    M. Colleen Hastings, Robert J. Wyatt, Keith K. Lau, Deborah P. Jones, Sandra L. Powell, Dena W. Hays, Lillian W. Gaber, A. Osama Gaber, Bettina H. Ault, Five years’ experience with thymoglobulin induction in a pediatric renal transplant population, Pediatric Transplantation, 2006, 10, 7
  66. 66
    Ajit P. Limaye, Ramasamy Bakthavatsalam, Hyung W. Kim, Sara E. Randolph, Jeffrey B. Halldorson, Patrick J. Healey, Christian S. Kuhr, Adam E. Levy, James D. Perkins, Jorge D. Reyes, Michael Boeckh, Impact of Cytomegalovirus in Organ Transplant Recipients in the Era of Antiviral Prophylaxis, Transplantation, 2006, 81, 12, 1645

    CrossRef

  67. 67
    Lorne N. Small, Joseph Lau, David R. Snydman, Preventing Post–Organ Transplantation Cytomegalovirus Disease with Ganciclovir: A Meta-Analysis Comparing Prophylactic and Preemptive Therapies, Clinical Infectious Diseases, 2006, 43, 7, 869

    CrossRef

  68. 68
    David R. Snydman, The case for cytomegalovirus prophylaxis in solid organ transplantation, Reviews in Medical Virology, 2006, 16, 5
  69. 69
    Mark D. Pescovitz, Valganciclovir, Transplantation Reviews, 2006, 20, 2, 82

    CrossRef

  70. 70
    Mark D Pescovitz, Valganciclovir: what is the status in solid organ transplantation?, Future Virology, 2006, 1, 2, 147

    CrossRef

  71. 71
    Raju Radha, Stanley Jordan, Dechu Puliyanda, Suphamai Bunnapradist, Anna Petrosyan, Nurmamet Amet, Mieko Toyoda, Cellular Immune Responses to Cytomegalovirus in Renal Transplant Recipients, American Journal of Transplantation, 2005, 5, 1
  72. 72
    D. R. Snydman, Counterpoint: Prevention of Cytomegalovirus (CMV) Infection and CMV Disease in Recipients of Solid Organ Transplants: The Case for Prophylaxis, Clinical Infectious Diseases, 2005, 40, 5, 709

    CrossRef

  73. 73
    J. Malaise, M.J. Ricart, A. Moreno, M. Crespo, L. Fernández-Cruz, D. Van Ophem, J.P. Squifflet, Cytomegalovirus Infection in Simultaneous Pancreas-Kidney Transplantation, Transplantation Proceedings, 2005, 37, 6, 2848

    CrossRef

  74. 74
    Scott A Gruber, James Garnick, Katherina Morawski, Dale H Sillix, Miguel S West, Darla K Granger, Jose M El-Amm, George J Alangaden, Pranatharthi Chandrasekar, Abdolreza Haririan, Cytomegalovirus prophylaxis with valganciclovir in African–American renal allograft recipients based on donor/recipient serostatus, Clinical Transplantation, 2005, 19, 2
  75. 75
    Stefan Schneeberger, Stefano Lucchina, Marco Lanzetta, Gerald Brandacher, Claudia B??sm??ller, Wolfgang Steurer, Fausto Baldanti, Clara Dezza, Raimund Margreiter, Hugo Bonatti, Cytomegalovirus-Related Complications in Human Hand Transplantation, Transplantation, 2005, 80, 4, 441

    CrossRef

  76. 76
    Abdolreza Haririan, Katherina Morawski, Dale H. Sillix, Jose M. El-Amm, James Garnick, Miguel S. West, Darla K. Granger, Stephen D. Migdal, Scott A. Gruber, Induction Therapy with Basiliximab versus Thymoglobulin in African-American Kidney Transplant Recipients, Transplantation, 2005, 79, 6, 716

    CrossRef

  77. 77
    N. Singh, Late-Onset Cytomegalovirus Disease as a Significant Complication in Solid Organ Transplant Recipients Receiving Antiviral Prophylaxis: A Call to Heed the Mounting Evidence, Clinical Infectious Diseases, 2005, 40, 5, 704

    CrossRef

  78. 78
    Julián Torre-Cisneros, Jesús Fortún, José María Aguado, Rafael de la Cámara, José Miguel Cisneros, Joan Gavaldá, Mercé Gurguí, Carlos Lumbreras, Carmen Martín, Pilar Martín-Dávila, Miguel Montejo, Asunción Moreno, Patricia Muñoz, Albert Pahissa, José Luis Pérez, Montserrat Rovira, Ángel Bernardos, Salvador Gil-Vernet, Yolanda Quijano, Gregorio Rábago, Antoni Román, Evaristo Varó, Recomendaciones GESITRA-SEIMC y RESITRA sobre prevención y tratamiento de la infección por citomegalovirus en pacientes trasplantados, Enfermedades Infecciosas y Microbiología Clínica, 2005, 23, 7, 424

    CrossRef

  79. 79
    David Axelrod, Joseph R. Leventhal, Lorenzo G. Gallon, Michele A. Parker, Dixon B. Kaufman, Reduction of CMV Disease with Steroid-Free Immunosuppresssion in Simultaneous Pancreas–Kidney Transplant Recipients, American Journal of Transplantation, 2005, 5, 6
  80. 80
    C. Vaessen, N. Kamar, M. Mehrenberger, C. Mazerolles, C. Mengelle, P. Rischmann, L. Rostaing, B. Malavaud, Severe cytomegalovirus ureteritis in a renal allograft recipient with negative CMV monitoring, Nephrology Dialysis Transplantation, 2005, 20, 1, 227

    CrossRef

  81. 81
    Atul Humar, Valganciclovir for cytomegalovirus prevention and treatment, Therapy, 2005, 2, 3, 333

    CrossRef

  82. 82
    Atul Humar, Valganciclovir for cytomegalovirus prevention and treatment, Therapy, 2005, 2, 3, 333

    CrossRef

  83. 83
    CURTIS D. HOLT, DREW J. WINSTON, Transplantation of the Liver, 2005,

    CrossRef

  84. 84
    2. Prophylaxis for Cytomegalovirus infection in patients following renal transplantation, Nephrology, 2004, 9, S3
  85. 85
    K. Keven, A. Basu, H.P. Tan, N. Thai, A. Khan, A. Marcos, T.E. Starzl, R. Shapiro, Cytomegalovirus prophylaxis using oral ganciclovir or valganciclovir in kidney and pancreas–kidney transplantation under antibody preconditioning, Transplantation Proceedings, 2004, 36, 10, 3107

    CrossRef

  86. 86
    Enver Akalin, Jonathan S. Bromberg, Vinita Sehgal, Scott Ames, Barbara Murphy, Decreased Incidence of Cytomegalovirus Infection in Thymoglobulin-Treated Transplant Patients with 6 Months of Valganciclovir Prophylaxis, American Journal of Transplantation, 2004, 4, 1
  87. 87
    Steven Gabardi, Colm C. Magee, Steven A. Baroletti, John A. Powelson, Jennifer L. Cina, Anil K. Chandraker, Efficacy and Safety of Low-Dose Valganciclovir for Prevention of Cytomegalovirus Disease in Renal Transplant Recipients: A Single-Center, Retrospective Analysis, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2004, 24, 10
  88. 88
    Graeme Forrest, Gastrointestinal infections in immunocompromised hosts, Current Opinion in Gastroenterology, 2004, 20, 1, 16

    CrossRef

  89. 89
    Ajit P. Limaye, Ramaswamy Bakthavatsalam, Hyung W. Kim, Christian S. Kuhr, Jeffrey B. Halldorson, Patrick J. Healey, Michael Boeckh, Late-Onset Cytomegalovirus Disease in Liver Transplant Recipients Despite Antiviral Prophylaxis1, Transplantation, 2004, 78, 9, 1390

    CrossRef

  90. 90
    David L. Bigam, A. M. James Shapiro, Pancreatic transplantation: Beta cell replacement, Current Treatment Options in Gastroenterology, 2004, 7, 5, 329

    CrossRef

  91. 91
    Robert M. Kotloff, Vivek N. Ahya, Stephen W. Crawford, Pulmonary Complications of Solid Organ and Hematopoietic Stem Cell Transplantation, American Journal of Respiratory and Critical Care Medicine, 2004, 170, 1, 22

    CrossRef

  92. 92
    Enver Akalin, Barbara Murphy, Vinita Sehgal, Scott Ames, Lisa Daly, Jonathan S Bromberg, Rapid steroid withdrawal in hepatitis C virus-positive kidney transplant recipients, Clinical Transplantation, 2004, 18, 4
  93. 93
    Andrew L. Campbell, Betsy C. Herold, Strategies for the prevention of cytomegalovirus infection and disease in pediatric liver transplantation recipients, Pediatric Transplantation, 2004, 8, 6
  94. 94
    Nina Babel, Leila Gabdrakhmanova, Jan-Steffen Juergensen, Nermin Eibl, Jan Hoerstrup, Markus Hammer, Christian Rosenberger, Conny Hoeflich, Ulrich Frei, Frank Rohde, Hans-Dieter Volk, Petra Reinke, Treatment of Cytomegalovirus Disease with Valganciclovir in Renal Transplant Recipients: A Single Center Experience, Transplantation Journal, 2004, 78, 2, 283

    CrossRef

  95. 95
    Raymund R Razonable, Carlos V Paya, Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts, Expert Review of Anti-infective Therapy, 2004, 2, 1, 27

    CrossRef

  96. 96
    D.J. Taber, E. Ashcraft, G.M. Baillie, S. Berkman, J. Rogers, P.K. Baliga, P.R. Rajagopalan, A. Lin, O. Emovon, F. Afzal, K.D. Chavin, Valganciclovir prophylaxis in patients at high risk for the development of cytomegalovirus disease, Transplant Infectious Disease, 2004, 6, 3
  97. 97
    A Mocarquer, V Pinto, E Buckel, E Lagos, J Pefaur, K Ramirez, J Morales, P Rosatti, A Elberg, Basiliximab: efficacy and tolerability in adults and children, Transplantation Proceedings, 2003, 35, 7, 2518

    CrossRef

  98. 98
    Irmeli Lautenschlager, Cytomegalovirus and solid organ transplantation: an update, Current Opinion in Organ Transplantation, 2003, 8, 4, 269

    CrossRef